Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.34 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.34 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CPN1 | P15169 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2148995 | 0.97 | EPHX1 (0.37) | GBA1SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL21940451 | 0.97 | EPHX1 (0.37) | GBA1SLC6A1GABRA5GABRB2SLC6A12 | |
| Hydrochloric Acid SCHEMBL38665760 | 0.97 | GBA1 (0.37) | GBA1SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL8297763 | 0.97 | EPHX1 (0.37) | GBA1SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL331996 | 0.91 | GBA1 (0.42) | GBA1SLC6A1GABRA5GABRB2SLC6A12 | |
| Piperazine SCHEMBL27857658 | 0.88 | CXCR4 (0.37) | EPHX1MEN1MAPTKMT2AATM | |
| SCHEMBL1241237 | 0.88 | GBA1 (0.41) | GBA1SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL21371574 | 0.86 | ALDH1A1 (0.42) | HRH3EPHX1CPN1CPB2HRH4 | |
| SCHEMBL491426 | 0.80 | NOS1 (0.39) | MEN1MAPTKMT2AATM | |
| SCHEMBL18930423 | 0.80 | SLC6A1 (0.43) | GBA1SLC6A1GABRA5GABRB2SLC6A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011524396-A | — | — | 2011-09-01 | — | — | JP | claimed |
| EP-2297096-A2 | ARYL KETONE AS MRI | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | claimed |
| US-20090318493-A1 | Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | claimed |
| WO-2009153178-A2 | ARYL KETONE AS MRI | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| EP-2297096-A2 | ARYL KETONE AS MRI | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-20090318493-A1 | Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| WO-2009153178-A2 | ARYL KETONE AS MRI | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
| EP-0848707-B1 | 4-(CYCLOALKYL)PIPERIDINES AND 4-(CYCLOALKYLALKYL)-PIPERIDINES DERIVATIVES, PREPARATION THEREOF AND THERAPEUTICAL APPLICATIONS THEREOF | SYNTHELABO (FR) | 1999-08-04 | — | — | EP | disclosed |
| CN-1201453-A | 4- (cycloalkyl) -piperidine and 4- (cycloalkylalkyl) piperidine derivatives, their preparation and their use in medicine | SYNTHELABO CO (FR) | 1998-12-09 | — | — | CN | disclosed |
| EP-0848707-A1 | 4-(CYCLOALKYL)PIPERIDINES AND 4-(CYCLOALKYLALKYL)-PIPERIDINES DERIVATIVES, PREPARATION THEREOF AND THERAPEUTICAL APPLICATIONS THEREOF | SYNTHELABO (FR) | 1998-06-24 | — | — | EP | disclosed |
| WO-1997009309-A1 | 4-(CYCLOALKYL)PIPERIDINE AND 4-(CYCLOALKYLALKYL)PIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTICAL APPLICATIONS THEREOF | SYNTHELABO (FR) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | GBA1 2652/4885SLC6A1 2645/4885GABRA5 1578/4885 |
| US-20090318493-A1 | Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | TPH2, TPH1, ADRA2C | GBA1 2527/4885SLC6A1 528/4885GABRA5 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.